参考文献：
[1]中华预防医学会疫苗与免疫分会. 子宫颈癌等人乳头瘤病毒相关疾病免疫预防专家共识[J]. 中华预防医学杂志, 2019, 53(8):761-803.
[2]刘桐宇, 谢榕. 人乳头瘤病毒E6、E7基因致癌机制及临床应用进展[J]. 中华生物医学工程杂志, 2013, 19(002):172-176.
[3]姚霞, 郝敏, 赵卫红. HPV整合宫颈上皮细胞机制的研究进展[J]. 现代妇产科进展, 2014(12):1007-1009.
[4]杨俊东、邢志芳、曹国君. 高危型人乳头瘤病毒的研究进展[J]. 检验医学与临床, 2020, v.17(23):20-23.
[5]王丽梅, 徐琳. HPVE6/E7 mRNA与宫颈病变关系的研究进展[J]. 四川解剖学杂志, 2015.
[6]walboomErs ,et al.J.PATHOL. 189:12-19(1999)
[7]Tjalma W , Depuydt C E . Cervical cancer screening: which HPV test should be used--L1 or E6/E7?[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 170(1):45-46.
[8] Middleton K , Peh W , Southern S , et al. Middleton K, Peh W, Southern S, Griffin H, Sotlar K, Nakahara T et al.Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J Virol 77:10186-10201[J]. Journal of Virology, 2003, 77(19):10186-10201.
[9]Tor Molden etc. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-Proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. International Journal of Cancer. Int. J. Cancer, 2005,114: 973–976.
